Intellia Therapeutics will report its Q4 and full-year 2024 results on February 27, 2025, during a conference call.
Quiver AI Summary
Intellia Therapeutics, Inc. will hold a conference call on February 27, 2025, at 8 a.m. ET to present its fourth quarter and full-year 2024 financial results and operational highlights. Participants can join by dialing specific numbers for U.S. and international callers, and a live webcast will also be available. A replay of the call will be accessible on Intellia’s website later that day. As a clinical-stage gene editing company, Intellia focuses on developing CRISPR-based therapies to address unmet medical needs and aims to set a new standard for gene editing technologies and treatments. For more information, visit their website or follow them on social media.
Potential Positives
- Intellia Therapeutics is set to present its fourth quarter and full-year 2024 financial results and operational highlights, indicating transparency and engagement with investors.
- The company emphasizes its focus on developing novel, first-in-class medicines, showcasing its commitment to addressing important unmet medical needs.
- Intellia's continued expansion of its CRISPR-based platform demonstrates innovation and the potential for future advancements in gene editing technology.
Potential Negatives
- Details of the fourth quarter and full-year 2024 financial results are pending, which may indicate potential weaknesses in performance or areas of concern that are not yet disclosed.
FAQ
What date will Intellia Therapeutics present its 2024 financial results?
Intellia Therapeutics will present its fourth quarter and full-year 2024 financial results on February 27, 2025.
How can I join the Intellia Therapeutics conference call?
To join the call, U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726.
What time does the Intellia Therapeutics conference call start?
The conference call will start at 8 a.m. ET on February 27, 2025.
Where can I find the replay of the conference call?
A replay of the call will be available on the Events and Presentations page of Intellia's website starting at 12 p.m. ET on February 27, 2025.
What is the focus of Intellia Therapeutics?
Intellia Therapeutics is focused on developing gene editing therapies using CRISPR technology to address unmet medical needs.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$NTLA Insider Trading Activity
$NTLA insiders have traded $NTLA stock on the open market 8 times in the past 6 months. Of those trades, 0 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $NTLA stock by insiders over the last 6 months:
- JOHN M LEONARD (President and CEO) sold 26,807 shares for an estimated $326,509
- DAVID LEBWOHL (EVP, Chief Medical Officer) sold 9,557 shares for an estimated $116,404
- LAURA SEPP-LORENZINO (EVP, Chief Scientific Officer) sold 8,966 shares for an estimated $109,205
- JAMES BASTA (EVP, General Counsel) sold 7,074 shares for an estimated $86,161
- DEREK HICKS (EVP, Chief Business Officer) sold 6,502 shares for an estimated $79,194
- MICHAEL P DUBE (VP, Chief Accounting Officer) has made 0 purchases and 2 sales selling 3,384 shares for an estimated $54,959.
- MUNA BHANJI sold 265 shares for an estimated $2,642
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$NTLA Hedge Fund Activity
We have seen 171 institutional investors add shares of $NTLA stock to their portfolio, and 155 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DEEP TRACK CAPITAL, LP removed 4,950,000 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $57,717,000
- FEDERATED HERMES, INC. removed 2,736,920 shares (-99.9%) from their portfolio in Q4 2024, for an estimated $31,912,487
- ALLIANCEBERNSTEIN L.P. removed 1,928,469 shares (-87.9%) from their portfolio in Q4 2024, for an estimated $22,485,948
- BALYASNY ASSET MANAGEMENT L.P. added 1,556,433 shares (+207.6%) to their portfolio in Q4 2024, for an estimated $18,148,008
- CITADEL ADVISORS LLC added 1,504,631 shares (+152.1%) to their portfolio in Q4 2024, for an estimated $17,543,997
- UBS GROUP AG added 1,463,336 shares (+525.6%) to their portfolio in Q4 2024, for an estimated $17,062,497
- PICTET ASSET MANAGEMENT HOLDING SA removed 1,394,911 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $16,264,662
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
CAMBRIDGE, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its fourth quarter and full-year 2024 financial results and operational highlights in a conference call on February 27, 2025, at 8 a.m. ET.
To join the call:
- U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All participants should ask to be connected to the Intellia Therapeutics conference call.
- Please visit this link for a simultaneous live webcast of the call.
A replay of the call will be available through the Events and Presentations page of the Investors & Media section on Intellia’s website at www.intelliatx.com , beginning on February 27, 2025, at 12 p.m. ET.
About Intellia Therapeutics
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. Since its inception, Intellia has focused on leveraging gene editing technology to develop novel, first-in-class medicines that address important unmet medical needs and advance the treatment paradigm for patients. Intellia’s deep scientific, technical and clinical development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies. Learn more at intelliatx.com and follow us @intelliatx .
Intellia Contacts:
Investors:
Brittany Chaves
Senior Manager, Investor Relations
[email protected]
